Amgen (AMGN) announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA reduced the risk of death by 40% and significantly extended median overall survival by more than five months compared to standard-of-care chemotherapy in patients with small cell lung cancer who progressed on or after one line of platinum-based chemotherapy. The results will be presented at the 2025 American Society of Clinical Oncology Annual Meeting and have been published in The New England Journal of Medicine.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Market Position and Growth Potential Drive Buy Rating
- Amgen assumed with a Neutral at Guggenheim
- Amgen price target lowered to $328 from $329 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Cautious Hold on Amgen: Navigating Competitive Challenges and Market Potential for MariTide